1 Frequently Asked Questions (FAQ s) The TNM Project Committee receives questions concerning the use of TNM and how to interpret rules in specific situations. Some questions and answers are listed below by category for your convenience. General questions 1. In situ carcinoma 1.1 Can one stage in situ carcinoma if the regional lymph nodes have not been assessed, e.g., in a completely resected colonic polyp? Although it is strictly NX (regional lymph nodes cannot be assessed), NX is assumed to be N0 because lymph node metastasis is not consistent with an in situ lesion. 1.2 High-grade dysplasia and carcinoma in situ How does one classify "carcinoma in situ" and "high grade dysplasia in Barrett esophagus" and in "colon polyps"? Our registry consultant provided the following: SEER rules say that high-grade dysplasia per se and severe dysplasia per se are not reportable to cancer registries. However, if the diagnosis is stated as "high-grade dysplasia (carcinoma in situ)", the case is reportable as 8140/2 based on the carcinoma in situ part of the diagnosis; in TNM it would be Tis. 1.3 Clinical and pathological stage A patient has a needle biopsy of a left upper lobe mass that is positive for squamous cell carcinoma. A CT of the thorax shows a 4-cm left upper lobe mass >2 cm from the carina. The clinical category is ct2. What is the pathologic classification? Biopsy alone is not sufficient for pathological staging in this instance. Resection of the primary tumour is needed for pt1 or pt2 lung tumours to define their limits. Biopsy, without resection, could be used, for example, for pt4 (showing invasion of the oesophagus). 1.4 R Classification Does R0 mean a complete tumour-free situation or is the R classification limited to the primary? R classification is not limited to the primary. The R classification not only considers locoregional residual tumour but also distant residual tumour in the form of unresected or incompletely resected metastases (R2) If there is residual tumour after surgery, is it stage IV? RX = Presence of residual tumour cannot be assessed R0 = No residual tumour R1 = Microscopic residual tumour R2 = Macroscopic residual tumour
2 R2 is not always synonymous with M1 (stage IV) disease. For example, in the absence of distant metastasis (M0), residual macroscopic primary tumour not or incompletely resected by the surgeon is R2. In another example, a metastasis in the liver from a primary gastric carcinoma would be M1 (stage IV) and R2 (if the metastasis was not resected). It would be pm1 (stage IV) and R0 if the metastasis was solitary and resected with tumour-free margins Does R status take into account the primary disease only or disease in the lymph node also, i.e. if nodes are left behind after complete resection of the primary do we call it R0? The R0 status concerns the entire body; if a clinically positive lymph node is left behind it is R2. If there are liver metastases it is R2. If a solitary liver metastasis is resected and no other tumour is evident, it is R R Classification and Tis Lumpectomy specimen of a breast tumour contains a 1.1-cm carcinoma with no invasive carcinoma at the resection lines; however, intraductal carcinoma was at the lateral resection line. How is this classified with respect to T category and R classification? The invasive carcinoma would be pt1 and R0. Although the in situ component is not considered in the R classification, an optional solution would be R1(is). 1.6 Positive Cytology If peritoneal washing cytology, taken before any other procedure during laparotomy is positive, how do I stage the patient? Grossly visible peritoneal metastasis were not found. Is it considered a form of peritoneal metastasis and thus stage IV? Positive cytology on lavage of the peritoneal cavity performed during laparoscopy or immediately after opening the abdomen (beginning of laparotomy) corresponds to M1 (except for tumours of corpus uteri, ovary and fallopian tube). Newer data suggest that the worsening of prognosis indicated by positive lavage cytology may have been overestimated. Thus it seems important to analyze such cases separately. For identification of cases with positive cytology from pleural or peritoneal washings as the sole basis for M1, the optional addition of "cy+" is recommended, e.g. M1(cy+) and in the R classification R1(cy+) may be used . 1.7 T0 and TX Explain the difference between T0 and TX. TX = Primary tumour cannot be assessed T0 = No evidence of primary tumour TX means you were not able to evaluate the tumour, e.g., the extent of a primary testis tumour requires radical orchiectomy; if there is no radical orchiectomy TX is used. T0 means that a primary tumour was not found by any clinical methods, e.g., if you found a cervical lymph node with metastatic squamous cell carcinoma and you examined the mouth, pharynx, and larynx and found no primary tumour, you would code T0(N1 M0) on the assumption that the primary was in the region. 1.8 Synchronous tumours What is the rule for classifying a synchronous versus a metachronous second primary tumour?
3 If a new primary cancer is diagnosed within two months, the new cancer is considered synchronous; otherwise it is metachronous (based on criteria used by the SEER Programme of the National Cancer Institute, USA). Metachronous tumours are classified separately from the preceding tumour. General rule No. 5 discusses the rules for classifying simultaneous (synchronous) tumours. 1.9 Single tumour cells and micrometastasis in lymph nodes How does one classify single tumour cells detected immunohistochemically in lymph nodes? There has been considerable debate in recent years on how to classify tumour cells in lymph nodes or bone marrow that are detected by immunohistochemical or molecular methods. An optional proposal to deal with this situation as subsets of N0. Single tumour cells should be distinguished from cases with morphologic evidence of micrometastasis, i.e., no metastasis larger than 0.2 cm . The latter can be identified by the addition of (mi) in the pn or pm categories as follows: pn1 (mi) = Regional lymph node micrometastasis pm1 (mi) = Distant micrometastasis 1.10 Number of lymph nodes If less than the desired number of lymph nodes is found, and none show metastasis, should it be classified as pnx or pn0? If the examined lymph nodes are negative, but the number ordinarily resected is not met, classify as pn0. The number of lymph nodes examined and the number involved by tumour should be recorded in the pathology report. This information may be added in parentheses, e.g., for colorectal carcinoma pn0 (0/10) or pn1 (2/11) Pathological assessment of distant metastasis Should liver metastasis diagnosed by fine-needle aspiration (FNA) be considered pm1 or pmx? The primary site is the breast. General rule 2 of TNM states, "The pathologic assessment of distant metastasis (pm) entails microscopic examination." This statement intentionally uses the term "microscopic" rather than "histologic" to allow for FNA and cytology. In this case the classification would be pm Classification of brain tumours The fourth edition of TNM included a classification for brain tumours. Why has this been left out of the fifth and sixth editions? The application of TNM to CNS tumours has not been successful. This particularly concerns the classification as a predictor of outcome. That carries little weight compared with other factors such as histological type, tumour location and patient age. The N does not apply at all, and the M rarely plays a role. This field is still under study to find other means of classifying CNS tumours that will carry prognostic significance. Further details may be obtained from the 6th edition AJCC Cancer Staging Manual  and from Ohgaki et al  Classification of primary peritoneal neoplasms How do you classify primary neoplasms of the peritoneum? We did not find any TNM classification for these tumours. Some of our colleagues use the FIGO/TNM ovary classification.
4 Because of the rarity of primary peritoneal neoplasms, there is indeed no TNM classification for them. Basically, there are two primary peritoneal entities: mesothelioma and primary carcinoma of the peritoneum. The latter, serous papillary carcinoma of the peritoneum, according to McCaughey et al  and Killackey and Davis 1993 , has the same prognosis as ovarian tumours. Therefore, one could apply the TNM ovarian tumour classification until a tested scheme is available. According to FIGO rules (24th Annual Report ), primary peritoneal carcinoma is classified as ovarian tumours. There are no proposals regarding peritoneal mesotheliomas Pathological versus clinical TNM Does the pathological TNM replace the clinical TNM? No. TNM is a dual system with a (pretreatment) clinical classification (ctnm or TNM) and a (postsurgical histopathological) pathological classification (ptnm). Both classifications are retained unaltered in the patient's record. The former is used for the choice of treatment; the latter is used for the estimation of prognosis and the possible selection of adjuvant therapy When in doubt If I am not sure of the correct T, N, or M category, e.g., because of unclear measurements, which do I select? Select the lower (i.e., less advanced) category. Example: Sonography of the liver shows a lesion suspicious but not definite for a metastasis. Select M0 (not M1) Tumour cells in lymphatics If I have a carcinoma of the colon with invasive tumour in the submucosa, but with lymphatics in the muscularis propria containing tumour cells, which do I select, T1 or T2? T1 (submucosa). The microscopic presence of tumour cells in lymph vessels or veins does not qualify as local spread in the T classification (except tumour cells in veins for liver and kidney). The optional L (lymphatic) and V (venous) classifications can be used to record such involvement. (See TNM 6th ed., p. 14. ) 1.17 Tumour spillage If tumour is spilled into the abdomen during surgery, how does this affect classification? Tumour spillage is considered only in the T classification of ovarian tumours. In the ovary, T1c, rupture of the capsule, includes spontaneous rupture and rupture during surgery. At other sites, it does not affect the TNM or stage grouping Simultaneous tumours I have a case of a colon with two carcinomas, one invasive into the muscularis propria and the other invasive into the submucosa. How do I code them? T2(m) or T2(2). When there are simultaneous (synchronous) tumours in one organ, the tumour with the highest T category is classified and the multiplicity (m) or number of tumours (2) is indicated in parentheses. If bilateral cancers occur simultaneously in paired organs, each tumour is classified independently. For carcinomas of the thyroid, liver, ovary, and fallopian tube multiplicity is a criterion of T classification. If a new primary cancer is diagnosed within 2
5 months, the new cancer is considered synchronous (criterion of the SEER Programme of the NCI, USA) Direct spread Is a tumour that has spread directly from a gastric primary into an adjacent regional lymph node coded in the T or N category? N category. Direct spread into a regional lymph node is classified as lymph node metastasis; direct spread into an adjacent organ, e.g., the liver from a gastric primary, is recorded in the T classification. (See TNM 6th ed., p. 9.) 1.20 N versus M For gastric carcinoma, when we find tumour nodules in the omentum, should we classify them as lymph node metastasis? Unless the nodules are in the lymphatic drainage region (regional lymph nodes) they should be considered distant metastasis and classified M1 or pm1. (See TNM 6th ed., p. 65.) 1.21 Recurrent tumour How can I classify a patient who had an apparently complete local excision of a carcinoma of the rectum, but was found, 2 years later, to have recurrent tumour at the same site? Use the Recurrent tumour, r symbol. There must be a documented disease-free interval to use this symbol. For example, rt0n0m0 would designate the status during the disease free interval and rt1n0m0 would indicate a recurrent tumour at the primary site (estimated clinically to be in the submucosa). After a second resection the result might be expressed as: rpt2pn1m0, if the resected tumour was found pathologically to be in the muscularis propria. In other cases, the recurrence in the area of the primary tumour may be indicated by "rt+". Example: Local recurrence after simple mastectomy, 2 cm in greatest dimension, with or without invasion of skin or chest wall: rt Unknown primary How do I classify a patient who has metastatic melanoma in a cervical lymph node less than 3 cm in greatest dimension without a primary or other metastasis? T0pN1M0, stage III. The staging is based on regional lymph node and/or distant metastasis status. In this case, the site of metastasis is assumed to be regional Neo-adjuvant therapy In a case of rectal carcinoma after neo-adjuvant chemo-radiotherapy there is a group of tumour cells in the muscularis propria floating in a pool of mucin. Such pools abound and are also seen in the subserosal layer but are without tumour cells. What would be the ypt category of this tumour? Since the definition of the "y" factor states that it categorizes tumour that is actually present, select ypt Is the "y" used in cases of preoperatively treated (by hormones, antihormones or chemotherapeutics) prostate carcinomas? The "y" can apply to all cases that are treated with any recognized antitumour therapy, e.g., hormones, antihormones, orchiectomy. It is easier than drawing a line among them. However, what does one do with a patient who has been on an antihormone (Tamoxifin) prophylactically
6 and then develops breast carcinoma? That should be excluded as there was no tumour prior to the administration of the drug AJCC versus UICC TNM Does the AJCC classification differ from the UICC TNM classification? No. The TNM classifications in the publications of the UICC and the American Joint Committee on Cancer (AJCC) are identical. They were formulated together, but appear in separate books, namely, the UICC TNM Classification of Malignant Tumours and the AJCC Cancer Staging Manual. Both are in their fifth editions and were published in 2002 [1, 8] Sentinel lymph node How do I classify sentinel lymph node status? The following is applicable when sentinel lymph node assessment is attempted: pnx(sn) = Sentinel lymph node could not be assessed pn0(sn) = No sentinel lymph node metastasis pn1(sn) = Sentinel lymph node metastasis Site-specific questions 2.1 Larynx Since the T classification of laryngeal tumours involves assessment of vocal cord fixation, does it mean that pt is not possible without such information given by the clinician? For pathological classification concerning impaired mobility or fixation of vocal cords, the information from the clinical T is used for the pathologic T. This is in accordance with TNM rule No. 2, pathological classification "is based on the evidence acquired before treatment, supplemented or modified by the additional evidence acquired from surgery and from pathological examination" Are sarcomatoid carcinomas of the larynx classified with TNM just like the squamous cell carcinomas? Yes, they are classified with the same criteria. It would be useful to separate sarcomatoid carcinomas from other types so that they can be analysed as a distinct group. 2.2 Oesophagus Is a tumour of the oesophagus with invasion of perioesophageal fatty tissue without infiltration of adjacent structures classified as pt3 or pt4? Does the perioesophageal fatty tissue belong to the mediastinum and thus to adjacent structures? The described situation is classified as pt3. The fatty tissue belongs to the adventitia and not to adjacent structures such as bronchus, heart, pericardial sac and aorta For tumours of upper thoracic oesophagus what is the difference between pn1 and pm1a, because the definition of regional lymph nodes of the cervical oesophagus includes supraclavicular lymph nodes?
7 For the thoracic oesophagus, including the upper thoracic, the cervical lymph nodes are not regional nodes. For the cervical oesophagus, the regional nodes are the cervical nodes. (See TNM 6th ed., p. 61.) Do you classify coeliac axis or left gastric artery nodes as M1 or N for an oesophageal cancer that involves the lower 5 cms of the oesophagus and spreads to the proximal 2 cm of the stomach with no other sites of disease apart from perioesophageal or perigastric nodes? Direct spread to the stomach by an oesophageal tumour makes the lymph nodes of the stomach regional and therefore they should be classified in the N classification (depending on number of involved lymph nodes) and not in M1/pM If you have an adenocarcinoma of the gastroesophageal junction should you use the TNM classification for an esophageal or gastric primary? In this case the TNM classification for stomach tumours should be used. 2.3 Colon and rectum How shall I classify a well-differentiated neuroendocrine carcinoma of the appendix (malignant carcinoid) with spread into mesoappendix? Is it pt3 (like adenocarcinomas)? Carcinoids are not covered by the TNM classification. However, if they are referred to as neuroendocrine carcinomas, they could be classified. In this case, you would use the criteria of the colon and consider it pt3. Appendiceal carcinomas should be separated from other colon cases and well differentiated neuroendocrine carcinomas should be separated from adenocarcinomas. This would ensure that analysis of data is more accurate both by site and histological type In carcinoma of the colon is a tumour that has reached the serosal surface classified as pt3 or pt4? What is the definition of reaching the serosa? In some places it is taken to be tumour that is within 1 mm of the serosal surface. T3 covers tumours in the subserosa, i.e., those beneath the serosal surface. T4 applies to tumours that "perforate visceral peritoneum", i.e., the serosal surface In adjuvant trials on colorectal carcinomas we make the distinction between T4a and T4b tumours as being the following: T4a = Invasion of other organs T4b = Penetration of the serosa How is the distinction made in the TNM Supplement? This distinction applies to tumours of the colon and rectum and is mentioned in this volume as an optional proposal for testing new telescopic ramifications of TNM. pt4a = Invasion of adjacent organs or structures pt4b = Perforation of visceral peritoneum In a patient with adenocarcinoma of the colon there was full-thickness penetration of the wall, 13 positive nodes and also a "free-floating" focus of carcinoma in the peritoneal cavity. No other peritoneal tumour was found Should that be staged as T0, TX or T1?
8 The case should be considered pm1, because there was tumour in the peritoneal cavity separate from the primary. The primary tumour would be pt3, or if it penetrated the serosa, pt4, and pn2 because of the number of nodes involved Is a rectal carcinoma that extends into the anus a T3 or a T4? The TNM Supplement states that: "Intramural direct extension from one subsite (segment) of the colon to an adjacent one is not considered in the T classification. The same applies to intramural direct extension from the rectum to the anal canal". The T category is determined by the depth of penetration Is a rectal carcinoma infiltrating the levators to be considered T3 or T4? We suggest coding a rectal carcinoma infiltrating the levators as T4 (invasion of adjacent structures). This is based on the poor prognosis difficulty in achieving an R0 state (no residual tumour) radical surgery required Does direct extension of a colorectal tumour into a lymph node constitute nodal metastasis and therefore N1? Yes, direct extension of any tumour into a lymph node is considered nodal metastasis Is a carcinoma of the colon that has reached the serosal surface (T4) with direct invasion of the omentum classified as M0 or M1? Direct extension to the omentum from a colon carcinoma is T4, not M Stomach In gastric carcinoma, is the presence of positive lymph nodes/tumour nodules in omentum considered N or M1? If they are close to the stomach (in the lymph drainage area) N 1-3 is likely; if they're far from the stomach, M1 seems reasonable. If you are in doubt, use TNM Rule No. 4, when in doubt choose the lower category (M0) In cancer of the stomach, how do I clinically stage invasion of omentum? A tumour that directly extends into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures, is classified T2b. If there is perforation of the peritoneum covering the gastric ligaments or omentum, the tumour is T3. Tumour in the omentum that is not connected to the primary and is not in a draining lymph node is considered M Pancreas In pancreatic cancer, does invasion of any portion of the common bile duct, including the intrapancreatic portion constitute tumour extending beyond the pancreas (pt3)? Also, when tumour invades into the adjacent peripancreatic fat, does only the retroperitoneal fat constitute invasion into peripancreatic tissues and therefore pt3? These would all be T3/pT Ampulla of Vater An adenocarcinoma of the ampulla of Vater penetrates through the sphincter of Oddi to involve the mucosa/submucosa on the outer surface of the ampulla. Is this a T2 because it penetrates the sphincter of Oddi, or a T1 because it is confined to the
9 ampulla? Also, the definition of T2 states "Tumour invades duodenal wall". What is meant by "wall"; i.e., what part(s) of the duodenum constitutes the "wall"? If the tumour goes beyond the ampulla and sphincter and doesn't reach the pancreas it is T2. The duodenal wall covers anything beyond the sphincter (submucosa, muscularis propria or adventitia). 2.7 Lung For lung carcinomas, does T2 invasion of visceral pleura mean perforation of pleural membrane? T2 invasion of visceral pleura includes either of the following: tumour reaches the elastic membrane of the visceral pleura tumour is present on the surface of the visceral pleura How do I classify a patient with a 2-cm primary adenocarcinoma of the right upper lobe of lung with multiple deposits of adenocarcinoma in the right lower lobe, negative lymph nodes and no other metastasis? This is M1 (separate tumour nodules in a different lobe). In case of microscopic confirmation of the tumour nodules it is pm For clinical staging of lung cancer: Do we need to measure the tumour size on the lung "window" or on the mediastinal "window" of CT scans? Perform the measurement on the "window" that is most accurate in your institution. Presumably, a diagnostic radiologist would be able to indicate which is the most accurate procedure Lung carcinoma. Is infiltration of hilar fat (perivenous or ligamentum pulmonale) T3 or T4? T Regarding adenocarcinoma of the lung with a predominantly bronchioloalveolar pattern of growth and a central area of scarring/invasion. Is the measurement of the tumour made on the overall size or is the T category based upon the greatest dimension of the invasive component only? Our pulmonary pathology consultant stated: Tumour size is based on total size - not just the invasive component. There are studies demonstrating prognostic importance of the size of the invasive component - but for staging purposes we use the total tumour size including the bronchioloalveolar component. For bronchioloalveolar carcinoma without invasion, tumour size is based on total size If a lower lobe lung cancer directly invades the upper lobe through pleura, is it T3? Direct invasion of an ipsilateral lobe through the pleura is T How is a second tumour nodule in the same lobe (satellite tumour) defined in the lung? Are there any criteria for (minimum) size or distance from main tumour? Criteria regarding size and distance from the main tumour have not been elaborated for satellites in the lung. 2.8 Breast
10 2.8.1 If the clinical T has been determined by physical examination as well as by mammography and ultrasonography, which measurement is used for the ct? For instance: Tumour palpated as 3 cm, mammography shows 2 cm, is it T2 to T1? According to a proposal in the TNM Supplement, the size for classification in this specific case is: cm cm = 2.5 cm and thus T Breast carcinoma 2.5 cm in diameter with invasion of the dermis/corium. Is this classified as pt2 or pt4? The criteria for classifying a breast tumour T4/pT4 include oedema, peau d'orange or ulceration of the skin of the breast and not invasion of the dermis. The tumour is classified as pt Infiltrating lobular carcinoma, cm, with extensive lymphovascular invasion. Pathology report: dermal lymphatics involved. Should this be classified as T4d (inflammatory carcinoma)? There was no clinical physical examination data available. Inflammatory carcinoma, T4d, requires the macroscopic (clinical) features to be present. Microscopic involvement of dermal lymphatic vessels alone does not count for classification. Tumour is T2 based on size Clinically with no palpable tumour, but with a mammogram showing suspicious microcalcifications. Physical examination did not show a tumour. Surgical removal of the lesion was diagnosed carcinoma in situ, questionable microinvasion. How is this classified? T0: clinically no evidence of primary tumour. ptis: carcinoma in situ. Questionable microinvasion leaves enough doubt to apply TNM rule no. 4: When in doubt choose the lower category In tumours of the breast, how do we classify invasion of lymphatic vessels in paranodal fatty tissue of the axilla with and without involvement of the axillary lymph nodes? Invasion of lymphatic vessels in the axilla is not considered in the TNM classification of breast tumours. The optional L (lymphatic) classification (TNM 6th ed., p. 14) can be used to describe lymphatic vessel involvement How does one classify an isolated tumour nodule in the axillary fat of a patient with breast carcinoma? It should be classified as lymph node metastasis, if it has the form and smooth contour of a lymph node. A tumour nodule with an irregular contour may be classified as venous axillary invasion (V classification) A 2.3-cm axillary lymph node had a small metastasis of cells 0.1 cm in size. How is that classified, according to the dimensions of the metastasis or to the dimensions of the lymph node? The size used for classification is the size of the measured metastasis not the size of the lymph node that contains the metastasis. The case would be classified as a micrometastasis (< or = 0.2 cm) and coded pn1mi In a case of Paget disease of the nipple with a small 0.3 cm tumour of the breast near the nipple, is this classified as pt1a or pt4?
11 This is classified pt1a. Paget disease associated with a tumour is classified according to the size of the tumour (TNM 6th ed., p ) How is microinvasive (<1 mm) breast cancer coded in the TNM? It is coded as T1mic How does one classify breast cancer after chemotherapy? Is ptpn appropriate? "In those cases in which classification is performed during or following initial multimodality therapy, the TNM or ptnm categories are identified by a y prefix" (TNM 6th ed., p. 14). For example, yt1n0m0 or ypt1pn0m The TNM Classification of Breast Tumours states: The clinical T1 category is further subclassified into T1mic, T1a, T1b, T1c. There was a discussion among physicians here as to why this was included in the clinical description as microscopic invasion can only be defined pathologically. Histologic examination is required on all clinical classifications for "confirmation of the disease". Pathologic classification, pt, requires more than histologic examination. It "requires the examination of the primary tumour with no gross tumour at the margins of resection". (See TNM 6th ed., p ) What is the pt category and the R status of a 1.5 cm breast carcinoma detected histologically in the resection margin? The pt category is pt1c and the R status R How does one classify a breast tumour with invasion of the nipple/mamilla with or without ulceration? The nipple is not considered in the definitions of the T classification. Size and ulceration are relevant criteria for the T category. Example. Breast carcinoma 1.9 cm in diameter with invasion of the nipple: With ulceration of the nipple = T4b/pT4b Without ulceration of the nipple = T1c/pT1c How do we classify a lymph node metastasis of breast cancer with a size of 1.8 mm and extension beyond the lymph node capsule? It should be classified as pn1mi, on the basis of its size. Extension beyond the capsule is no longer used as a criterion for pn classification If you have greater than 3 axillary lymph nodes with metastatic deposits of breast cancer all measuring less than 2mm would the case be classified as pn1(mi) or pn2? It is pn1mi. The pn2a definition states that at least one node is larger than 2mm In the staging of nodal involvement in breast cancer when there is exclusively sinusoidal involvement in breast cancer (no parenchymal infiltration, no stromal reaction, no vessel wall infiltration) that exceeds 0.2mm (in my case it measures 0.3 mm), how should it be classified: as pn0 (i+) or as pn1mi? pn1mi. Even if the sinusoidal tumour cells were less than 0.2 mm, unless they were truly isolated cells or small aggregates (< a half dozen cells per clump) they should not be included as pn0(i+).
12 Should we classify a malignant phylloides tumour of the breast according to the TNM system, and if so should we apply the soft tissue sarcoma or the carcinoma rules? It should not be classified by TNM soft tissue sarcoma criteria. There is controversy over whether the breast criteria should or should not be used How do I stage a breast cancer which has 3 separate invasive nodules measuring 3 cm, 4 cm and 2 cm respectively, separated by uninvolved breast tissue? pt2(3). The largest tumour is used for classification and the number of tumours is added in parentheses For breast carcinomas which measurements are more accurate, from the fresh specimen or the fixed tumour? Measurements of the unfixed tumour are preferred to the fixed specimen because of shrinkage after fixation. 2.9 Corpus uteri A uterine corpus tumour extends into the parametrium. Should it be classified as T2 or T3a? T3a. T2 tumours invade the cervix but do not extend beyond the uterus A radical hysterectomy specimen shows an adenocarcinoma penetrating the serosal surface (pt3a) of the corpus uteri. All regional lymph nodes were negative, but there was metastatic adenocarcinoma in parametrial soft tissue. Does this change the stage of the tumour? T3a includes "discontinuous involvement of adnexa and serosa within the pelvis" Ovary versus uterus A patient has a high grade (serous and clear cell) carcinoma confined to endometrium with peritoneal implants including surface of both ovaries, a small focus in one ovary and a large omental cake. Should we stage this as an ovarian tumour (M0) or an endometrial tumour (M1)? It would be very unusual for a superficial endometrial primary to produce an omental mass. Most would treat this as a primary ovarian lesion with a superficial second primary in the endometrium, making it a Stage IIIC ovarian with a Stage IA endometrial tumour Ovary The patient has a primary ovarian cancer. Ovaries were not removed. Laparotomy shows a 2 cm epiploic metastasis of papillary serous adenocarcinoma. Should I stage this tumour, ct3b or pt3b, or something else? Even though the ovaries are not removed, if you have microscopic confirmation of a 2 cm peritoneal metastasis outside the pelvis, pt3b is correct. (See TNM Supplement) How do I stage ovarian clear cell carcinoma with direct invasion through the wall of the sigmoid colon? T2b/ IIB if the invasion of the sigmoid is within the pelvis and T3/III if outside the pelvis; and depending on the size, substaged as B or C, accordingly.
13 2.12 Prostate During a radical prostatectomy for transitional cell carcinoma, if we find a clinically unexpected bilateral prostatic adenocarcinoma, should we consider it as incidental (pt1) or as a pt2 tumour? pt How do you classify prostate tumour extension into the bladder in a prostatectomy specimen? Invasion of the bladder is classified as T4/pT Penis How do you classify a squamous cell carcinoma that invaded deeply (beyond subepithelial tissue) into the cavernous tissue of the glans (not involving urethra)? T2/pT How do we classify perineural spread of prostatic carcinoma in extracapsular tissue? pt3a 2.14 Testis For malignant germ cell tumours of testis: To call a tumour pt2, is it the visceral tunica vaginalis or the parietal tunica vaginalis that has to be involved? Any invasion of tunica vaginalis would be pt Kidney We resected a renal cell carcinoma. Histology showed a small focus of tumour in the peripelvic fat and tumour invasion into blood vessels. What would be the T category? Invasion of the peripelvic fat would place this case into pt3a category. Histologic identification of blood vessel involvement does not justify pt3b as this specifically requires grossly visible invasion. (See TNM 6th ed., p ) In the TNM for renal cell carcinoma, a tumour which involves the adrenal gland is stated as T3. It is not stated, however, this is referring to the ipsilateral kidney. Is spread to the contralateral kidney M1? Direct spread to the contralateral adrenal gland, as well as to contralateral kidney, is M We resected a renal cell carcinoma of less than 7 cm limited to the kidney with a metastasis in the adrenal gland, no direct invasion, do we call this T3a M0 or T1b M1? We would consider the adrenal tumour as M1 if spread is not by direct invasion Urinary bladder For carcinoma of the bladder, if there is involvement of the seminal vesicle, should it be regarded as pt4a?
14 If the wall of the seminal vesicle or stroma of the prostate are involved, it should be T4a. If there is only in situ carcinoma in the seminal vesicle, it should not be classified T4. There are data that CIS in the prostatic ducts does not adversely impact survival  How do you classify a solitary lymph node metastasis of a bladder carcinoma with the metastasis smaller than 2cm and the lymph node larger than 8cm: is it pn1 or pn3? pn1. For the pn classification, the measurement is of the tumour, not the entire node. However, for the clinical assessment, cn, the size of the entire node is used. References 1. AJCC Cancer Staging Manual. 6th ed. Greene FL, Page D, Morrow M, Balch C, Haller D, Fritz A, Fleming ID, eds. New York: Springer; FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. 24th vol. Pecorelli S, Beller U, Heintz APM, Benedet JL, Creasman WT, Pettersson F, eds. J Epidemiol Biostatist 2001; 6: Hermanek P, Hutter RVP, Sobin LH, Wittekind Ch. Classification of isolated (disseminated, circulating) tumour cells and micrometastasis. Cancer 1999; 86: Killackey MA, Davies AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993; 51: McCaughey WT, Schryer MJ, Lin X, et al. Extraovarian pelvic serous tumour with marked calcification. Arch Pathol Lab Med 1986; 110: Montie JE, Wojno K, Klein E, et al. Transitional cell carcinoma in situ of the seminal vesicles: 8 cases with discussion of pathogenesis, and clinical and biological implications. J Urol 1997; 158: Ohkagi H, Reifenberger G, Nomura K, Kleihues P. "Brain Tumours: Gliomas". In: Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch (eds) UICC Prognostic Factors in Cancer. 2nd ed. Wiley Liss: New York, pp UICC. TNM Classification of Malignant Tumours. 6th ed. Sobin LH, Wittekind Ch (eds) Wiley- Liss: New York, 2002
CONTINUING EDUCATION PET Evaluation of Lung Cancer* Tira Bunyaviroch, MD 1 ; and R. Edward Coleman, MD 2 1 Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts; and 2 Duke
The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name
Standards and datasets for reporting cancers Dataset for the histological reporting of mesothelioma April 2013 Authors Professor Andrew G Nicholson, Royal Brompton Hospital and Harefield NHS Trust Professor
For reference only Do Not Use For more information contact: firstname.lastname@example.org Lung Cancer Pathology Data Standards June 2008 National Clinical Dataset Development Programme (NCDDP) Support Team Information
250 Thorax 2001;56:250 265 BTS statement Statement on malignant mesothelioma in the United Kingdom British Thoracic Society Standards of Care Committee Correspondence to: Dr J Wiggins, Wexham Park Hospital,
Contemporary Management of Malignant Pleural Mesothelioma ERIC G. BUTCHART University Hospital of Wales, Cardiff, United Kingdom Key Words. Mesothelioma Surgery Radiotherapy Chemotherapy Immunology Gene
Original Article Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases William G. Richards, PhD 1,2 ; John J. Godleski, MD 2,3 ; Beow Y.
SELECTIVE SCREENING OF LUNG CANCER CASES Steven Laird Laird & Jones, L.L.P. 2400 Scott Avenue Fort Worth, Texas 76103-2245 817-531-3000 Lung cancer is the number one cancer killer of American men and women.
South East London Cancer Network Lung Tumour Working Group Clinical Guidelines 2012 1. Aims of Lung Tumour Working Group South East London Cancer Network...1 Lung Tumour Working Group Clinical Guidelines
What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. AFIP ARCHIVES 583
E U R O P E A N J O U R NA L O F CA N C E R45 (2009) 228 247 available at www.sciencedirect.com journal homepage: www.ejconline.com New response evaluation criteria in solid tumours: Revised RECIST guideline
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of the
Eur Respir J 2010; 35: 479 495 DOI: 10.1183/09031936.00063109 CopyrightßERS Journals Ltd 2010 ERS/ESTS TASK FORCE Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons
Cancer Treatment & Survivorship Facts & Figures 14-15 Estimated Numbers of Cancer Survivors by State as of January 1, 14 OR 185,73 CA 1,661,74 WA 332,9 NV 18, ID 66,6 UT 81,26 MT 52,3 WY 29,8 CO 211,67
Anatomic Pathology / Malignant Pleural Mesothelioma Histologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy Andrea V. Arrossi, MD, 1 E. Lin,
December 5, 2005 Technical Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynecologic Malignancy
Cancer Facts & Figures 2015 CA 172,090 OR 22,410 WA 38,180 NV 13,640 AK 3,700 ID 8,080 UT 11,050 MT 5,950 WY 2,860 CO 24,540 MN 29,730 IA 17,140 AZ OK 32,440 NM 19,280 AR 9,970 15,830 HI 6,730 ND 3,840
CHAPTER 2 Tumours of the Pleura Mesothelioma is the most frequent neoplasm affecting the pleura and remains a major health threat for many years to come. Although the causation by asbestos is firmly established
BREATHE EASY HOW RADIOLOGY HELPS TO FIND AND FIGHT LUNG DISEASES TABLE OF CONTENTS 3 BREATHE EASY TABLE OF CONTENTS 4 INTRODUCTION: AN OVERVIEW OF CHEST IMAGING 9 CHAPTER 1: Lung imaging: the techniques
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
Handheld Radiofrequency Spectroscopy for Intraoperative Margin Assessment During Breast-Conserving Surgery Assessment Program Volume 28, No. 4 August 2013 Executive Summary Background Breast-conserving
MedSolutions, Inc. Clinical Decision Support Tool Diagnostic Strategies This tool addresses common symptoms and symptom complexes. Imaging requests for patients with atypical symptoms or clinical presentations
A Review of the Definition for Multiple Primary Cancers in the United States Workshop Proceedings From December 4-6, 2002, in Princeton, New Jersey Editor: Holly L. Howe, Ph.D. Executive Director NAACCR
Global Cancer Facts & Figures 2nd Edition Estimated Number of New Cancer Cases by World Area, 2008* 15 14 9 17 16 12 10 3 13 7 6 5 11 20 2 1 19 8 21 4 18 Worldwide* 12,667,500 1 Eastern Africa (221,100)
Anatomic Pathology / MALIGNANT PERITONEAL MESOTHELIOMA IN WOMEN Malignant Peritoneal Mesothelioma in Women A Study of 75 Cases With Emphasis on Their Morphologic Spectrum and Differential Diagnosis Patricia
RESECTION MARGINS, EXTRAPLEURAL NODAL STATUS, AND CELL TYPE DETERMINE POSTOPERATIVE LONG-TERM SURVIVAL IN TRIMODALITY THERAPY OF MALIGNANT PLEURAL MESOTHELIOMA: RESULTS IN 183 PATIENTS David J. Sugarbaker,